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Objective: The ﬁrst multicenter randomized controlled trial was designed and conducted to assess the safety and effec-
tiveness of totally percutaneous endovascular aortic aneurysm repair (PEVAR) with use of a 21F endovascular stent graft
system and either an 8F or 10F suture-mediated closure system (the PEVAR trial, NCT01070069). A noninferiority trial
design was chosen to compare percutaneous access with standard open femoral exposure.
Methods: Between 2010 and 2012, 20 U.S. institutions participated in a prospective, Food and Drug Administratione
approved randomized trial to evaluate percutaneous femoral artery access and closure by a “preclose” technique in
conjunction with endovascular abdominal aortic aneurysm repair. A total of 151 patients were allocated by a 2:1 design to
percutaneous access/closure (n [ 101) or open femoral exposure (n [ 50 [FE]). PEVAR procedures were performed
with either the 8F Perclose ProGlide (n [ 50 [PG]) or the 10F Prostar XL (n [ 51 [PS]) closure devices. All endo-
vascular abdominal aortic aneurysm repair procedures were performed with the Endologix 21F proﬁle (outer diameter)
sheath-based system. Patients were screened by computed tomography with three-dimensional reconstruction and in-
dependent physician review for anatomic suitability and adequate femoral artery anatomy for percutaneous access. The
primary trial end point (treatment success) was deﬁned as procedural technical success and absence of major adverse
events and vascular complications at 30 days. An independent access closure substudy evaluated major access-related
complications. Clinical utility and procedural outcomes, ankle-brachial index, blood laboratory analyses, and quality of
life were also evaluated with continuing follow-up to 6 months.
Results: Baseline characteristics were similar among groups. Procedural technical success was 94% (PG), 88% (PS), and
98% (FE). One-month primary treatment success was 88% (PG), 78% (PS), and 78% (FE), demonstrating noninferiority
vs FE for PG (P [ .004) but not for PS (P [ .102). Failure rates in the access closure substudy analyses demonstrated
noninferiority of PG (6%; P[ .005), but not of PS (12%; P[ .100), vs FE (10%). Compared with FE, PG and PS yielded
signiﬁcantly shorter times to hemostasis and procedure completion and favorable trends in blood loss, groin pain, and
overall quality of life. Initial noninferiority test results persist to 6 months, and no aneurysm rupture, conversion to open
repair, device migration, or stent graft occlusion occurred.
Conclusions: Among trained operators, PEVAR with an adjunctive preclose technique using the ProGlide closure device is
safe and effective, with minimal access-related complications, and it is noninferior to standard open femoral exposure.
Training, experience, and careful application of the preclose technique are of paramount importance in ensuring suc-
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Table I. Patient selection criteria
- Man or woman at least 18 years old
- Informed consent form understood and signed and patient agrees to all follow-up visits
- Abdominal aortic aneurysm with maximum diameter $5 cm or rapidly expanding
- Have a suitable ipsilateral CFA for percutaneous access with a preclose technique
- At least 2-cm segment for access, 10 mm above the origin of the profunda femoris branch and 10 mm below the lower margin of the
inferior epigastric artery as determined on preoperative high-resolution contrast-enhanced computed tomography scan
- Calciﬁcation of CFA target area not covering entire anterior wall, not present circumferentially, and not >50% of the circumference
from the posterior wall
- Absence of: prior groin incision; hematoma or signiﬁcant scarring at the ipsilateral arterial access site; clip-based vascular closure device
placement ever; collagen-based vascular closure device placement in either arterial access site within prior 90 days; femoral artery needle
puncture in either arterial access site within the prior 30 days
- Absence of: active localized groin infection; traumatic vascular injury; femoral artery aneurysm, arteriovenous ﬁstula, or pseudoaneurysm
- Anatomically eligible for the Endologix System per the indications for use
- Life expectancy >1 year as judged by the investigator
- Absence of: allergy to any device component; coagulopathy or uncontrolled bleeding disorder; active systemic infection; connective
tissue disease; prior renal transplant
- Serum creatinine level #1.7 mg/dL (unless dialysis dependent)
- Free from cerebrovascular accident or myocardial infarction within 3 months of enrollment
- No planned major intervention or surgery within 30 days after the study procedure
- Not morbidly obese (body mass index <40 kg/m2)
CFA, Common femoral artery.
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facilitate rapid and secure common femoral artery (CFA)
hemostasis after diagnostic or interventional procedures
with 5F to 8F sheaths and up to 10F sheaths (Perclose Pro-
Glide [PG] and Prostar XL [PS], respectively; Abbott
Vascular, Inc, Redwood City, Calif). Owing to the utility
of these closure devices, their use has been adapted to
CFA closure in conjunction with large-sheath endovascular
aortic aneurysm repair (EVAR). This requires use of a more
complex, closure device-speciﬁc “preclose” technique. This
concept was ﬁrst described for PS in 19991 and for PG in
2007.2 Technique feasibility has been reported in several
single-center experiences, with each using various large-
bore sheaths.2-19 Among these reports, percutaneous
EVAR (PEVAR) technical success rates of 71% to 96%
(PS) and 88% to 98% (PG) are reported with improvement
over time and increasing experience. Limited operator expe-
rience7,10 and “hostile” femoral anatomy3,4,9,10 have been
identiﬁed as predictors of technical failure, whereas larger
sheath diameter was inconsistently predictive. In observa-
tional reports of PEVAR and standard femoral exposure
(FE) EVAR, beneﬁts attributed to PEVAR included shorter
procedure times,6,16 lower complication rates9,12,15,17 and
shorter hospital stays.9,14 One single-center randomized pi-
lot study reported PS technical success in 14 of 15 PEVAR
cases, with signiﬁcantly reduced times to procedure comple-
tion and ambulation among PEVAR patients.5
Despite this growing experience, no multicenter,
randomized trial was previously available delineating
the risks and beneﬁts of PEVAR facilitated with an
adjunctive pre-close technique. Therefore, we conducted
the ﬁrst prospective, multicenter, randomized controlled
trial of PEVAR using an endograft system incorporating
a precannulated contralateral limb that is indicated for
standard contralateral percutaneous (9F) access (Endo-
logix, Inc, Irvine, Calif).20 Because of the prevalent
use of PG and PS, both were included in the trial. Wehypothesized that PEVAR would be noninferior to stan-
dard EVAR/FE.
METHODS
Twenty U.S. centers having prior training and experi-
ence in EVAR using both standard FE and suture-
mediated closure device preclose percutaneous techniques
participated. Each investigator was required (1) to provide
evidence of prior Abbott training and experience in the
use of the closure devices for small hole closure, (2) to com-
plete the Endologix EVAR training program, and (3) to
certify more than 20 PEVAR preclose cases before trial
participation. Each site obtained institutional review board
approval for human investigation, and written patient
informed consent was obtained. Before initiation of the trial
randomized phase, all sites were required to complete two
PEVAR “roll-in” cases.20 Preoperatively, high-resolution,
contrast-enhanced computed tomography (CT) scan imag-
ing with three-dimensional reconstruction (M2S, Inc, West
Lebanon, NH) of the thoracic and abdominal aorta was per-
formed to determine anatomic eligibility. To verify a suitable
access artery for the preclose procedure, additional assess-
ments of CFA dimensions and quality were conducted by
an independent vascular surgeon with experience in percuta-
neous endovascular techniques. Physical examinations, ankle-
brachial indices (ABI), and blood laboratory evaluations were
performed. These baseline assessments were used to deter-
mine patient suitability for enrollment (Table I). Health-
related quality of life (QOL)was also assessed before and after
the procedure by the Medical Outcomes Study short form
SF-36 tool (Medical Outcomes Trust, Boston, Mass).21
Randomization/patient allocation
Randomization was conducted by study site, using two
block sizes (3 or 6) with random choice of block size order.
One set of sealed randomization envelopes was provided
to each site after completion of roll-in cases and on sponsor
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bility conﬁrmation, the next sequential randomization enve-
lope was opened and the assignment was immediately
allocated. An overall 2:1 randomization scheme (PEVAR:FE)
was used to allow equal allocation to two PEVAR groups: PG
or PS. Trial enrollment was deﬁned as the time of procedure
initiation. Two patients who were randomized but never
enrolled (one withdrew consent; one did not meet cardiac
clearance requirements) were excluded from analysis.
Procedural conduct
In centers where the operator was an interventionist, a
qualiﬁed surgeon was required to be present in all PEVAR
cases in the event that surgical cutdown or intervention was
needed. At initiation of PEVAR procedures, appropriate
ipsilateral CFA puncture was documented angiographically
in an oblique projection. For FE-randomized patients, the
study protocol reﬂected a vascular cutdown to be per-
formed by a small oblique incision with direct exposure
and control of the femoral artery from inguinal ligament
to the femoral bifurcation. Management of the arteriotomy
with a purse-string suture vs formal clamping and a trans-
verse arteriotomy was left to the surgeon’s preference.
The selected endograft was then implanted under ﬂuoros-
copy. Anticoagulant was administered on establishing ac-
cess with a targeted activated clotting time of more than
250 seconds. In all cases, postdeployment graft posi-
tioning/aneurysm exclusion was conﬁrmed angiographic-
ally. Arteriotomy closure was performed by the preplaced
sutures as described later in PEVAR groups or direct artery
repair with a standard polypropylene-sutured closure fol-
lowed by layered wound closure in FE patients. Hemostasis
and preserved distal ﬂow were to be conﬁrmed, or any
complications identiﬁed were to be addressed immediately
intraoperatively, in all patients regardless of access type
before procedure completion. Anticoagulation reversal
was used selectively at the operator’s discretion.
All patients received a single intravenous preoperative
dose of antibiotics and were admitted for at least overnight
observation. Times of ambulation and normal diet were
recorded. Clinical examination, laboratory/ABI testing,
and femoral ultrasound (US) examinations were performed
before discharge. Patients were asked to grade their groin
pain bilaterally with a 10-point visual analog scale (0 ¼
none; 10 ¼ worst imaginable). One-month follow-up
included clinical examination, laboratory/ABI testing,
CT scan, SF-36 QOL, and groin pain assessments. Final
6-month follow-up included these same clinical assess-
ments, with repeated femoral US examination and optional
CT scans at the investigator’s discretion.
Device description
The Endologix endograft system consisted of a unibody
bifurcated device preloaded into a 21F proﬁle (outer diam-
eter) delivery system containing an integrated 19F intro-
ducer sheath. After seating of the bifurcated device at the
aortoiliac bifurcation, the inner core was removed, leaving
the hemostatic sheath in place. Additional devices, if needed,were advanced through this same sheath to complete the
repair. Details of the stent-graft design and anatomic ﬁxation
technique are available.22,23
The design and application of the PG and PS devices in
preclose techniques have been described.11,22,24 Brieﬂy,
each PG includes a single monoﬁlament polypropylene su-
ture having a pretied knot, whereas each PS delivers two
braided polyester sutures without a pretied knot. Arterial ac-
cess was obtained percutaneously at an oblique angle (w45)
with or without US guidance at operator discretion. A small
skin opening was made to permit PG or PS advancement,
limited blunt dissection of subcutaneous tissues was allowed,
and the closure devicewas advanced over a 0.035-inch guide-
wire and deployed. Two sutures were placed in each arterio-
tomy by use of either two PG devices sequentially deployed
with opposite 30 rotation in a “cross-hair” conﬁguration
or a single PS device, and suture tails were secured.
EVAR was performed following standard practice. On
ﬁnal sheath removal, the preplaced sutures were secured
over the guidewire. In PG cases, the pretied knots were
advanced to the CFA access site to achieve hemostasis; in
PS cases, a ﬁsherman’s knot was tied manually for each su-
ture set. At operator discretion, an additional device and
supplemental manual compression were applied as needed.
Skin closure was per operator preference (eg, Steri-Strip,
single absorbable suture, adhesive). In cases in which he-
mostasis was not achieved or limb ischemia was suspected,
closure failure was determined and surgical cutdown with
arterial repair employed.
Deﬁnitions
Table II provides study protocol deﬁnitions. The pri-
mary end point of treatment success reﬂects the comparison
in overall EVAR strategies between total percutaneous ac-
cess and conventional femoral exposure. The substudy end
point of access site closure looks more directly at the tech-
nical success of femoral vessel closure.
Statistical analyses
Primary end point: Treatment success. Sample size
was based on literature-based feasibility data, identifying
a minimum sample size of 44 patients per group. To ac-
count for deviations from assumptions, a sample size of 50
per group was targeted. Primary end point analysis was
performed by a one-sided Blackwelder test for non-
inferiority within a margin of 0.10 and a ¼ .025. No other
allowance for multiple comparisons was made. This
strategy provided >80% power for end point detection.
Analyses were conducted at exact time points: 1 month ¼
30 days; 6 months ¼ 210 days. An independent Clinical
Events Committee adjudicated adverse events, and an
independent Data Safety Monitoring Board reviewed
safety data. For continuous variables, summary statistics
included means and standard deviations; groups were
compared by t-tests. For ordinal variables, group com-
parisons were typically performed by the exact Wilcoxon
rank-sum test. Comparisons of proportions use Fisher
exact test. P < .05 deﬁned statistical signiﬁcance. Analyses
Table II. Protocol-speciﬁed deﬁnitions
Term Deﬁnition
Procedural technical success Successful vascular access and closure per randomized assignment, and successful endograft
delivery, deployment, and catheter removal, without serious complication or need for
vascular exposure in the percutaneous group
Closure device technical success Successful vascular access per randomized assignment and closure without serious complication
or need for vascular exposure in the percutaneous group. This includes successful deployment
and function of the closure device itself in the percutaneous group.
Major adverse events All-cause mortality; aneurysm rupture; bowel ischemia; cardiac morbidity (acute myocardial
infarction/cardioversion; pacemaker placement/new onset; exacerbated congestive heart
failure/surgical or percutaneous coronary intervention); conversion to open repair; neurologic
complications (paraplegia, spinal ischemia, stroke, transient ischemic attack); renal failure
(temporary or permanent dialysis; >0.5 mg/dL increase in serum creatinine level from
baseline); respiratory complications (pneumonia or respiratory failure requiring ventilator
support >24 hours postoperatively); and secondary procedure for type I/III endoleak
Vascular complications Arteriovenous ﬁstula; femoral neuropathy; hematoma requiring drainage or surgical intervention;
hemorrhage (access site bleeding requiring blood transfusion or surgical or percutaneous
intervention); infection; lymphocele; vascular (iliac or femoral artery) injury or
pseudoaneurysm requiring surgical repair; stenosis, distal emboli or thrombosis/occlusion;
and ABI reduction $0.15 from baseline not attributable to disease progression
Treatment success (primary
end point)
Composite end point inclusive of procedural technical success and absence of major adverse
event or vascular complication at 1 month
Major ipsilateral access site vascular
complications (independent access
site closure substudy end point)
Access site related: vascular injury requiring surgical repair, angioplasty, US-guided compression,
or thrombin injection; new-onset lower extremity ischemia attributed to arterial access or
closure requiring intervention; bleeding requiring transfusion; infection requiring intravenous
antibiotics or prolonged hospitalization; nerve injury (permanent or requires surgery)
Times to hemostasis, ambulation,
and normal diet
Time from sheath removal: to ﬁrst observed complete cessation of CFA bleeding; to when the
patient walks independently a minimum of 20 feet; and to tolerance of solid food
consumption
ABI, Ankle-brachial index; CFA, common femoral artery; US, ultrasound.
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Institute, Cary, NC).
Independent access site closure substudy. The safety
and effectiveness of PG and PS were assessed separately in
ipsilateral 21F access site closure (1-month major ipsilateral
access site vascular complications) in comparison to FE.
Analysis was performed by a one-sided Blackwelder test for
noninferiority with a margin of 0.10 and a ¼ .05.RESULTS
Enrollment/procedural outcomes. Fig 1 shows
randomization and patient allocation. Among 179 con-
senting/screened patients, 153 were found eligible and
randomized between July 2010 and February 2012. Rea-
sons for screen failure included unsuitable anatomy for the
endograft, poor CFA quality (eg, circumferential calciﬁca-
tion, pseudoaneurysm), morbid obesity (body mass index
>40), and inadequate CT scan quality. Excluding the two
randomized/nonenrolled patients, 151 were enrolled with
2:1 allocation to PEVAR (n ¼ 101) or FE (n ¼ 50).
PEVAR patients were divided by closure device: PG (n ¼
50) and PS (n ¼ 51). Among the 18 sites participating in
the randomized phase, 9 used PG, 7 used PS, and 2 used
both. Preoperative group comparisons among the three
groups are shown in Table III (demographics), Table IV
(comorbidities), and Table V (aneurysm and vascular
characteristics). Baseline characteristics were typical of this
population, and groups were well matched.Table VI shows procedural access technique/closure
device use. All patients underwent the assigned treatment.
Ipsilateral preclose access was attempted in all PEVAR
cases; surgical cutdown was performed in all FE cases.
US-guided percutaneous access was used in 36% (PG)
and 27% (PS); in the remainder, anatomic landmarks
were ﬂuoroscopically visualized. In all cases, angiographic
imaging conﬁrmed appropriate access location. Procedural
technical success in the roll-in phase was 95% (21 of 22 PG
and 18 of 19 PS), with both acute failures to achieve hemo-
stasis resolved with surgical cutdown/vessel repair. Ran-
domized phase procedural technical success among PG,
PS, and FE groups was 94% (47 of 50), 88% (45 of 51),
and 98% (49 of 50), respectively. In PG, three ipsilateral
preclose failures occurred: two surgical cutdowns for exces-
sive bleeding or to resolve stenosis at the femoral bifurca-
tion and return to the operating room for percutaneous
stent placement to address signiﬁcant stenosis. In PS, six
technical failures occurred: surgical cutdown for excessive
bleeding (5) and rheolytic thrombectomy/iliac stenting
for thrombosis. Three PS bleeding events were associated
with technique problems (ie, needle nonengagement with
artery wall, suture break at knot tying, pull-out from ar-
tery). Among PEVAR technical failures, US guidance was
used in two of three (PG) and two of six (PS). In FE,
one external iliac dissection with excessive bleeding
required switching to the lower-proﬁle Endologix AFX sys-
tem (19F outer diameter) for EVAR and external iliac ar-
tery stenting. Standard percutaneous (9F) access and
Randomization 2:1 
(N=153)
Screening Submissions            
(N=179)
Reasons for Screen Failure  (26)
• Aneurysm anatomy: 58%
• Poor CFA quality: 23%
• Morbid obesity (BMI>45): 15%
• Poor quality CT: 3.8%
Not Treated/Enrolled (N=2)
• Cardiac clearance
• Withdrew consent
SEVAR 
(N=50)
PEVAR 
(N=101)
PS Preclose 
(N=51)
PG Preclose 
(N=50)
Endovascular AAA Repair using the 
Endologix 21Fr Profile System (ipsilateral) 
Contralateral Access
• Per assignment (limb extension)
• 9Fr standard percutaneous
PRE-DISCHARGE EVALUATION + FEMUS PEVAR/PS (N=51)PEVAR/PG (N=50)
1-MONTH EVALUATION + CT SCAN
6-MONTH EVALUATION + FEMUS SEVAR (N=42)PEVAR/PG (N=48)
• Death (n=1)
• Withdrawn (n=3)
• Refused (n=2)
• Missed (n=2)
• Withdrawn (n=2)
SEVAR (N=50)
PEVAR/PG (N=50) SEVAR (N=50)PEVAR/PS (N=50)
PEVAR/PS (N=43)
• Death (n=1)
• Death (n=1)
• Withdrawn (n=4)
• Missed (n=2)
Fig 1. Patient ﬂow diagram. AAA, Abdominal aortic aneurysm; BMI, body mass index; CFA, common femoral artery;
CT, computed tomography; FEMUS, femoral ultrasound; PEVAR, percutaneous endovascular aortic aneurysm repair;
PG, ProGlide; PS, Prostar XL; SEVAR, standard endovascular aortic aneurysm repair.
Table III. Baseline demographics
Characteristic PEVAR/PG (n ¼ 50) PEVAR/PS (n ¼ 51) FE (n ¼ 50) PG vs FEa PS vs FEa
Age, years 70 6 6.6 74 6 11 73 6 8.8 .033 .984
Gender
Male 47 (94) 44 (86) 45 (90) .715 .760
Female 3 (6.0) 7 (14) 5 (10)
Race
White 46 (92) 44 (86) 47 (94) 1.000 .318
Nonwhite 4 (8.0) 7 (14) 3 (6.0)
ASA
Class 1 or 2 18 (36) 39 (76) 30 (60) .014 .077
Class 3 or 4 32 (64) 12 (24) 20 (40)
Height, cm 179 6 6.9 173 6 9.7 175 6 8.5 .122 .079
Weight, kg 93 6 13 83 6 19 86 6 15 .017 .025
Body mass index 29 6 3.9 28 6 4.7 28 6 4.7 .115 .922
ASA, American Society of Anesthesiology; FE, femoral exposure; PEVAR, percutaneous endovascular aortic aneurysm repair; PG, ProGlide; PS, Prostar XL.
Results shown as number (% of group) or as mean 6 standard deviation.
aP values determined by a two-sided Wilcoxon rank-sum test or two-sided Kruskal-Wallis test for singly ordered table (ASA class).
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90% PS; 84% FE). The remaining patients received 17F
outer diameter Endologix limb extensions. In these cases,
patients underwent the same preclose technique or FE
per randomization assignment. All contralateral access
techniques, implants, and closures were successful. Signiﬁ-
cantly fewer PG patients underwent concomitant ipsilateral
vascular procedures (2% PG vs 16% FE and PS; P < .01)
including iliac artery stenting, embolectomy, hypogastric
artery coiling, and CFA endarterectomy or reconstruction.Table VII shows procedural results. Local anesthesia
per physician preference was used in 16% PG, 37% PS,
and 24% FE patients. Time to hemostasis was signiﬁcantly
reduced in PEVAR groups vs FE (P < .002). Mean total
procedure time was signiﬁcantly shorter by 34 minutes
(PG) and 46 minutes (PS) vs FE (P < .001). Several
nonsigniﬁcant trends favoring one or both PEVAR groups
were observed: (1) reduced mean blood loss; (2) fewer PG
patients requiring transfusion; (3) hospital discharge on
average a half-day earlier; and (4) fewer PEVAR patients
Table IV. Baseline comorbidities
Characteristic PEVAR/PG (n ¼ 50) PEVAR/PS (n ¼ 51) FE (n ¼ 50) PG vs FEa PS vs FEa
Arrhythmia 17/50 (34) 15/51 (29) 13/50 (26) .513 .821
Cancer 10/50 (20) 15/51 (29) 16/50 (34) .254 .831
Cerebrovascular accident 3/50 (6.0) 6/51 (12) 2/50 (4.0) 1.000 .269
Chronic obstructive pulmonary disease 15/50 (30) 15/51 (29) 17/50 (34) .831 .672
Coagulopathy or uncontrolled bleeding
disorder
0 0 0 d d
Congestive heart failure 8/50 (16) 7/51 (14) 11/50 (22) .611 .309
Coronary artery disease 19/50 (38) 26/51 (51) 24/50 (48) .419 .843
Diabetes 14/50 (28) 15/51 (29) 11/50 (22) .645 1.000
Family history of abdominal aortic
aneurysm
11/50 (22) 5/50 (10) 9/50 (18) .388 .388
Gastrointestinal abnormality 26/50 (52) 20/51 (39) 29/50 (58) .688 .074
Heart valve disease 4/50 (8.0) 9/51 (18) 4/50 (8.0) 1.000 .234
Hypertension 42/50 (84) 45/51 (88) 44/50 (88) .774 1.000
Hyperlipidemia 45/50 (90) 46/51 (90) 42/50 (84) .554 .389
Liver disease 5/50 (10) 2/51 (3.9) 1/50 (2.0) .204 1.000
Myocardial infarction 6/50 (12) 12/51 (24) 8/50 (16) .774 .455
Peripheral arterial occlusive disease 7/50 (14) 11/51 (22) 7/50 (14) 1.000 .437
Prior abdominal surgery 13/50 (26) 14/51 (27) 11/50 (22) .815 .646
Prior aortic valve repair or replacement 0 1/51 (2.0) 0 d 1.000
Prior coronary artery bypass grafting 9/50 (18) 13/51 (25) 13/50 (26) .470 1.000
Prior pacemaker or implantable
cardioverter-deﬁbrillator implant
2/50 (4.0) 12/51 (24) 3/50 (6.0) 1.000 .023
Prior percutaneous coronary intervention 10/50 (20) 10/51 (20) 10/50 (20) 1.000 1.000
Renal failure 1/50 (2.0) 0 2/50 (4.0) 1.000 .243
Smoking 43/50 (86) 35/51 (69) 34/50 (68) .056 1.000
Thoracic aortic aneurysm 0 1/51 (2.0) 2/50 (4.0) .495 .617
FE, Femoral exposure; PEVAR, percutaneous endovascular aortic aneurysm repair; PG, ProGlide; PS, Prostar XL.
Results shown as number (% of group).
aP values determined per two-sided Fisher exact test.
Table V. Baseline aneurysm and vascular characteristics
Measurement or characteristic PEVAR/PG (n ¼ 50) PEVAR/PS (n ¼ 51) FE (n ¼ 50) PG vs FEa PS vs FEa
Maximum aneurysm sac diameter, mm 56 6 6.1 53 6 6.3 56 6 8.1 .715 .096
Proximal nonaneurysmal neck diameter, mm 22 6 3.4 23 6 3.2 24 6 2.8 .031 .951
Distal nonaneurysmal neck diameter, mm 26 6 3.6 26 6 3.3 25 6 3.6 .115 .390
Proximal neck length, mm 30 6 13 27 6 13 29 6 12 .700 .320
Irregular proximal neckb 40 41 42 1.000 1.000
Neck angle to sac, degrees 28 6 15 26 6 15 30 6 14 .702 .235
Distal renal to aortic bifurcation length, mm 121 6 26 108 6 15 110 6 23 .010 .032
Aortic bifurcation diameter, mm 25 6 9.4 26 6 11 32 6 40 .294 .656
Narrow aortic bifurcationc 20 14 16 .602 1.000
Right common iliac artery diameter, mm 12 6 2.7 13 6 2.1 14 6 3.9 .062 .107
Right external iliac artery diameter, mm 8.9 6 1.9 9.2 6 1.5 12 6 13 .156 .211
Bifurcation to right hypogastric artery length, mm 55 6 18 51 6 21 54 6 35 .843 .560
Left common iliac artery diameter, mm 13 6 2.8 12 6 2.1 13 6 3.0 .561 .675
Left external iliac artery diameter, mm 8.8 6 1.5 12 6 15 9.2 6 1.3 .093 .376
Bifurcation to left hypogastric artery length, mm 59 6 20 52 6 25 56 6 32 .585 .387
FE, Femoral exposure; PEVAR, percutaneous endovascular aortic aneurysm repair; PG, ProGlide; PS, Prostar XL.
Results shown as % of group or as mean 6 standard deviation.
aP values determined per two-sided Wilcoxon rank-sum test, two-sided unequal variance t-test, or Fisher exact test.
bDeﬁned as >2-mm diameter change over the ﬁrst 15 mm of length.
cDeﬁned as diameter <21 mm.
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differences were observed in times to ambulation or normal
diet. Prolonged hospital stay occurred in ﬁve patients
because of spinal ischemia (FE [17 days]); stroke, renal fail-
ure, and respiratory failure (FE [6 days]); signiﬁcantbleeding and re-exploration of the groin/extended incision
secondary to distal ischemia with postoperative hypoten-
sion monitored and resolved (FE [6 days]); heart failure
and 33% ABI reduction (PS [6 days]); and contrast ne-
phropathy (PG [5 days]).
Table VI. Procedural access technique and closure
devices used
Technique
PEVAR/PG
(n ¼ 50)
PEVAR/PS
(n ¼ 51)
FE
(n ¼ 50)
Ipsilateral
Preclosea (successful) 48 (96) 46 (90) 0
Preclose a/ cutdown 2 (4.0) 5 (9.8) 0
Cutdown 0 0 50 (100)
Contralateral
Precloseb 4 (8.0) 5 (9.8) 0
Cutdown 0 0 8 (16)
Standard percutaneous
(9F sheath)
46 (92) 46 (90) 42 (84)
Angio-Sealc 14 4 12
Manual compression 0 11 6
ProGlide 32 11 17
Prostar XL 0 18 7
StarClosed 0 2 0
FE, Femoral exposure; PEVAR, percutaneous endovascular aortic aneurysm
repair; PG, ProGlide; PS, Prostar XL.
Results shown as number (% of group).
aThe group closure device (PG or PS) was used in a preclose technique.
bThe group closure device (PG or PS) was used in a preclose technique
before limb extension placement (17F outer diameter).
cSt. Jude Medical, Inc (St Paul, Minn).
dAbbott Vascular, Inc (Redwood City, Calif).
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or FE groups. In PS, one patient withdrew (day 7) and one
cardiac death occurred (day 28). Two late cancer deaths
occurred on days 75 (PS) and 201 (FE). Excluding
patients who withdrew consent or refused/missed the visit,
48 PG, 43 PS, and 42 FE patients completed ﬁnal 6-month
follow-up.
Primary end point analysis. Treatment success results
are shown in Table VIII. Compared with FE (78%), non-
inferiority was achieved for PG (88%; P ¼ .004) but not for
PS (78%; P ¼ .102). On analysis of results by site, no
signiﬁcant trends were identiﬁed between randomized
groups. Adjustment for baseline covariates with P < .10
did not alter these results. Procedural technical failures
were described previously. Although the incidence of major
adverse events and vascular complications were similar
among groups, the overall rate trended lower in PG (12%)
vs PS (22%) or FE (22%).
Events by group were as follows:
d PG: Ipsilateral distal thrombosis in two patients mani-
fested as loss of pedal pulses and Doppler signals
immediately after the procedure due to posterior
plaque-induced stenosis at the CFA bifurcation in
which endarterectomy/patch angioplasty restored
perfusion; loss of Doppler signal after the procedure
in one patient attributed to stenosis was resolved
with stenting.
d PS: Iliofemoral thrombosis in one patient was
managed with rheolytic thrombectomy of the external
iliac/CFA followed by stenting.
d FE: Acute lower extremity ischemia in two patients
discovered after initial wound closure was addressedwith immediate reoperation and endarterectomy/
patch angioplasty after the index procedure; one
CFA occlusion on day 7 was treated with thrombec-
tomy/patch angioplasty.
Independent access site closure substudy analysis.
One-month results are shown in Table IX. Compared with
FE (10% failure), noninferiority was achieved for PG (6%;
P ¼ .005) but not for PS (12%; P ¼ .100). A 10% PS rate
would have achieved noninferiority per Blackwelder test.
Events by group were as follows:
d PG: inability to complete the preclose technique with
the closure device because of bleeding and distal
thrombosis (2).
d PS: inability to complete the preclose technique with
the closure device because of bleeding (3), vascular
injury/bleeding repaired surgically (2), iliofemoral
thrombosis, and transfusion for bleeding.
d FE: vascular injury (groin re-exploration with bilateral
endarterectomy/patching), distal thrombosis (2),
transfusion for bleeding, bleeding/vessel dissection
requiring surgical repair/stenting/transfusion, and
nerve injury (persistent thigh numbness).
Other 1-month outcomes. Serious adverse events are
shown in Table X. Compared with the incidence rate in
FE (26%), a trend toward reduced serious adverse events
was seen in PG (10%; P ¼ .066) with similar incidence in
PS (31%). The incidence of individual events was low. No
speciﬁc trends were identiﬁed. Comparable mean ABI and
laboratory results were observed. Fig 2 shows SF-36 QOL
results among all eight domains in two dimensions,
physical and mental health. Reductions in 1-month mean
scores were observed for both role limitation domains;
slightly less reduction occurred in PEVAR groups. Overall
mean scores were similar at each time point, although 1-
month changes were greater in PG (þ9) and PS (þ6) vs
FE (0). Pain scale results are provided in Fig 3 showing
relatively low groin pain bilaterally. Compared with FE,
prescribed analgesics for groin pain trended lower in PG
(18% vs 34%; P ¼ .241) and were signiﬁcantly lower in PS
(12% vs 34%; P ¼ .039).
Final 6-month outcomes. Fig 4 shows the 6-month
Kaplan-Meier analysis of treatment success. The 1-month
noninferiority analysis results persisted (PG vs FE, P ¼
.008; PS vs FE, P ¼ .118). Between days 31 and 210, 3
PG, 4 PS, and 4 FE patients (one of whom had an early
event) were identiﬁed with a major adverse event or
vascular complication; there were no major access-related
complications. Late major adverse events and vascular
complications included the following: PG: renal failure
treated medically and two ABI decreases/no intervention;
PS: cancer death (day 75), critical left renal artery stenosis
requiring stenting, three secondary procedures for endo-
leak (days 41, 54, and 121), and ABI decrease/no inter-
vention; FE: cancer death (day 201), two secondary
procedures for endoleak (days 81, 131), and lymphocele.
Table VII. Procedural and in-hospital outcomes
Measurement or characteristic PEVAR/PG (n ¼ 50) PEVAR/PS (n ¼ 51) FE (n ¼ 50) PG vs FEa PS vs FEa
Activated clotting time achieved, seconds 257 6 51 257 6 39 260 6 55 .778 .759
Contrast volume, mL 120 6 78 123 6 56 144 6 90 .113 .172
Fluoroscopy time, minutes 26 6 16 22 6 8.5 24 6 14 .433 .359
Estimated blood loss, mL 213 6 205 193 6 198 280 6 290 .115 .083
Blood transfusion 4.0 16 14 .187 1.000
Procedure time, minutes 107 6 45 95 6 35 141 6 73 .006 <.001
Ipsilateral time to hemostasis, minutes 9.8 6 17 13 6 19 23 6 23 .002 <.001
Time to ambulation, hoursb 17 6 7.2 16 6 9.1 19 6 16 .388 .256
Time to normal diet, hoursc 14 6 9.4 10 6 8.4 15 6 22 .728 .135
ICU length of stay, hours 26 6 9.0 31 6 15 35 6 38 .269 .614
Medication for groin pain 18 12 30 .241 .029
Time to hospital discharge, days 1.3 6 0.7 1.4 6 0.9 1.8 6 2.4 .135 .213
FE, Femoral exposure; ICU, intensive care unit; PEVAR, percutaneous endovascular aortic aneurysm repair; PG, ProGlide; PS, Prostar XL.
Results shown as % of group or as mean 6 standard deviation.
aP values determined per an unequal variance two-sample t-test or Fisher exact test.
bCalculated as time from sheath removal to time patient walks 20 feet.
cCalculated as time from sheath removal to time patient consumes solid food.
Table VIII. Primary end point results: Treatment success at 1 month
Outcome PEVAR/PG (n ¼ 50) PEVAR/PS (n ¼ 51) FE (n ¼ 50) PG vs FE PS vs FE
Treatment success 44 (88) 40 (78) 39 (78) .004a .102a
Unsuccessful (failure) treatmentc 6 (12) 11 (22) 11 (22) .287b 1.000b
Procedural technical failure 3 (6.0) 6 (12) 1 (2.0) .242b .027b
Ipsilateral access failure 3 (6.0) 6 (12) 0
Endovascular device failure 0 0 1 (2.0)
Major adverse event 2 [3] (4.0) 5 [7] (9.8) 5 [7] (10) .436b .741b
Death 0 1 [1] (2.0) 0
Aneurysm rupture 0 0 0
Conversion to open repair 0 0 0
Bowel ischemia 0 0 0
Cardiac morbidity 0 2 [2] (3.9) 0
Neurologic complication 0 0 3 [3] (6.0)
Renal failure 2 [2] (4.0) 1 [1] (2.0) 1 [1] (2.0)
Respiratory complication 1 [1] (2.0) 2 [2] (3.9) 1 [1] (2.0)
Secondary procedure 0 1 [1] (2.0) 2 [2] (4.0)
Vascular complication 4 [5] (8.0) 8 [9] (16) 8 [11] (16) .357b 1.000b
Arteriovenous ﬁstula 0 0 0
Femoral neuropathy 0 0 1 [1] (2.0)
Hematoma 0 0 0
Hemorrhage 1 [1] (2.0) 4 [5] (7.8) 3 [4] (6.0)
Infection 0 0 0
Lymphocele 0 0 1 [1] (2.0)
Thrombosis/occlusion 2 [3] (4.0) 1 [1] (2.0) 3 [3] (6.0)
Vascular injury 1 [1] (2.0) 3 [3] (5.9) 1 [2] (2.0)
Major adverse event þ vascular complication 6 [8] (12) 11 [16] (22) 11 [18] (22)
FE, Femoral exposure; PEVAR, percutaneous endovascular aortic aneurysm repair; PG, ProGlide; PS, Prostar XL.
Results shown as number of patients (% of group) except for major adverse events and vascular complications, which are shown as number of patients [number
of events] (% of group).
Major adverse events and vascular complication events included the following: PG: serum creatinine increases (2), pneumonia, bleeding repaired surgically,
distal thrombosis (2), and ankle-brachial index (ABI) decrease; PS: cardiac death, congestive heart failure (2), dialysis, pneumonia, secondary angiography (to
rule out endoleak), bleeding repaired surgically (5), iliofemoral thrombosis, femoral pseudoaneurysm, and decreased bilateral ABI; FE: stroke, transient
ischemic attack, spinal ischemia, serum creatinine increase, 2-day postoperative intubation, secondary interventions (angiographic endoleak rule out and type
Ia endoleak repair), persistent thigh numbness, blood transfusion (2), bleeding/vessel dissection requiring surgical repair/transfusion, lymphocele, distal
thrombosis (2), bilateral endarterectomy/patching, and ABI decrease due to stenosis.
aP values determined per one-sided Blackwelder test (noninferiority).
bP values determined per two-sided Fisher exact test.
cThe total number of patients with procedural technical failure, a major adverse event, or a vascular complication.
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Table IX. Independent ipsilateral access site closure substudy results at 1 month
Outcome PEVAR/PG (n ¼ 50) PEVAR/PS (n ¼ 51) FE (n ¼ 50) PG vs FEa PS vs FEa
Major access-related complications 3 (6.0) 6 (12) 5 (10) .005 .100
Vascular injury 1 (2.0) 5 (10) 1 (2.0)
Lower extremity ischemia 2 (4.0) 1 (2.0) 2 (4.0)
Bleeding/transfusion 1 (2.0) 1 (2.0) 2 (4.0)
Nerve injury 0 0 1 (2.0)
FE, Femoral exposure; PEVAR, percutaneous endovascular aortic aneurysm repair; PG, ProGlide; PS, Prostar XL.
Results shown as number (% of group). Some patients experienced >1 event.
aP values determined per one-sided Blackwelder test (noninferiority).
Table X. Serious adverse events at 1 month
System organ class
PEVAR/PG
(n ¼ 50)
PEVAR/PS
(n ¼ 51)
FE
(n ¼ 50) PG vs FEa PS vs FEa
Patients with $1 serious adverse event 5 [10] (10) 16 [28] (31) 13 [23] (26) .066 .661
Blood and lymphatic system disordersb 1 [1] (2.0) 1 [1] (2.0) 3 [3] (6.0) .617 .362
Cardiac disorders 0 2 [2] (3.9) 0 d .495
Gastrointestinal disorders 0 1 [1] (2.0) 1 [1] (2.0) 1.000 1.000
General disorders/administration site conditions 1 [1] (2.0) 3 [3] (5.9) 1 [1] (2.0) 1.000 .618
Infections and infestations 1 [1] (2.0) 3 [3] (5.9) 0 1.000 .243
Injury, poisoning, and procedural complications 0 1 [1] (2.0) 1 [1] (2.0) 1.000 1.000
Investigations 3 [4] (6.0) 1 [1] (2.0) 4 [5] (8.0) 1.000 .362
Metabolism and nutrition disorders 1 [1] (2.0) 1 [1] (2.0) 0 1.000 1.000
Nervous system disorders 0 1 [1] (2.0) 3 [3] (6.0) .242 .362
Renal and urinary disorders 2 [2] (4.0) 4 [4] (7.8) 2 [2] (4.0) 1.000 .678
Respiratory, thoracic, and mediastinal disorders 0 2 [3] (3.9) 2 [2] (4.0) .495 1.000
Surgical and medical procedures 0 1 [1] (2.0) 0 d 1.000
Vascular disorders 0 4 [5] (7.8) 4 [5] (8.0) .118 1.000
FE, Femoral exposure; PEVAR, percutaneous endovascular aortic aneurysm repair; PG, ProGlide; PS, Prostar XL.
Results shown as number of patients [number of events] (% of group). Some patients experienced >1 event.
aP values determined per two-sided Fisher exact test.
bBlood and lymphatic system disorders detail by study arm: PEVAR/PG: anemia on postoperative day 1, treated by transfusion (two units of packed red blood
cells); PEVAR/PS: anemia beginning on postoperative day 2, treated with blood transfusion; standard FE: intraprocedural hemorrhage of 1500 mL treated
with nine units of packed red blood cells, anemia on postoperative day 1 treated with two units of packed red blood cells, and exacerbation of anemia
beginning on the day of the procedure treated by blood transfusion.
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observed. No stent fracture, device obstruction/occlusion,
migration, or aneurysm sac increase was seen in any patient.
DISCUSSION
This trial provides strong evidence for the safety and
efﬁcacy of totally percutaneous EVAR incorporating a
preclose technique using the ProGlide suture-mediated
closure device. Both academic and community institutions
participated, with vascular surgeons (70%) and interven-
tional specialists (30%) as part of a multidisciplinary team
to permit broader assessment of PEVAR. Suitable, deﬁned
patient selection criteria were applied, and we have observed
excellent outcomes in a representative patient population.
Roll-in and trial phase technical success rates were similar
for PEVAR/PG but were disparate for PEVAR/PS. This
may suggest a difference in preclose technique-speciﬁc re-
quirements necessary to ensure success.
With this study design, primary noninferiority of
PEVAR/PG vs FE was achieved with respect to treatment
success at both 1 and 6 months. A low incidence of PG ma-
jor access-related complications was observed (6%).Technical failure primarily resulted in inadequate hemosta-
sis control, but distal ischemia and access vessel stenosis
were also observed. The PEVAR/PS arm did not achieve
noninferiority in part because of a higher rate of technical
failures. The rate of failures seen in the standard approach
EVAR/FE arm probably reﬂects the active investigation
and oversight mandated by the protocol and the indepen-
dent adjudication incorporated into this trial. This degree
of oversight was applied to all arms equally, however.
The raw numbers of failures in both the PEVAR/PS and
the FE groups were small, however, so further evaluation
is likely to be warranted.
Clinical utility beneﬁts after PEVAR included signiﬁ-
cantly reduced times to hemostasis and procedure comple-
tion. Nonsigniﬁcant trends favoring PEVAR were observed
with respect to blood loss and time to hospital discharge.
Our mean times to ambulation (16-19 hours) were shorter
than those reported in the only single-center randomized
trial (20-33 hours),5 probably representing improved over-
all protocols. Overall 6-month mortality among the cohort
is low (1.0%), with few serious adverse events in late follow-
up, reﬂecting excellent standard of care among trial sites.
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Fig 2. SF-36 quality-of-life questionnaire results over time. A, Percutaneous endovascular aortic aneurysm repair
(PEVAR) ProGlide (PG) group results. B, PEVAR Prostar XL (PS) group results. C, Standard femoral exposure (FE)
group results. The horizontal axis shows the SF-36 domain: PF, Physical function; RP, role limitation, physical; RE,
role limitation, emotional; VT, vitality;MH, mental health; SF, social functioning; PN, bodily pain; GH, general health;
overall.
Fig 3. Ipsilateral groin pain. P values calculated by a two-sample
t-test. FE, Femoral exposure; PEVAR, percutaneous endovas-
cular aortic aneurysm repair; PG, ProGlide; PS, Prostar XL.
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support the generalizability of totally percutaneous EVAR
with this sheath-based endograft system and the ProGlide
closure device using the study patient selection criteria.
Patient selection criteria were applied to permit a realistic
group comparison while avoiding inappropriate patient
anatomies (eg, circumferential CFA calciﬁcation). Conse-
quently, two groups in particular are not adequately
addressed by these results. First, morbidly obese patients
were excluded (body mass index cutoff of 40 kg/m2);
however, many think that this population may realize thegreatest beneﬁt of PEVAR because of morbidity reduction
associated with groin incisions. Single-center evidence sug-
gests PEVAR safety in the morbidly obese,14 but we
cannot conclude such. Second, our cohort included only
9.9% women, making broad generalization difﬁcult.
Consistent with recent reports that female patients are
anatomically less likely to meet device eligibility criteria
for EVAR in general25 or for PEVAR,16 only a small num-
ber of women met our inclusion criteria. Treatment success
in women among groups in this study was similar (7 of 10
PEVAR; 4 of 5 FE), consistent with single-center studies
suggesting PEVAR to be safe in carefully selected
women.16 Appropriate caution should be taken in expand-
ing the applicability of this technique.8,14
Additional study limitations are noted. US guidance for
CFA location/puncture was strongly recommended but
not protocol mandated. The relatively infrequent use
among study sites probably represents physician experience
and comfort with PEVAR without US guidance. Although
there are reports that US guidance aids in precise CFA pre-
close punctures and is a predictor of technical success,26-28
its limited use in this trial did not inﬂuence PG success;
nonetheless, it is not clear to what extent this inﬂuenced
PS success. Also, the choice of anesthetic strategy was left
up to the implanting physicians. Although local anesthesia
or monitored anesthesia care has been suggested for
PEVAR,17 utilization in this trial was limited, so no speciﬁc
conclusions can be drawn. This probably represents the
comfort of each study site with local anesthesia protocols
Fig 4. Treatment success composite end point Kaplan-Meier analysis. CL, Conﬁdence limit; FE, femoral exposure;
PEVAR, percutaneous endovascular aortic aneurysm repair; PG, ProGlide; PS, Prostar XL.
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was generally used during the trial). Mandated use of local
anesthesia in the PEVAR arm would have biased results. It
stands to reason that local anesthesia becomes more attrac-
tive with PEVAR adoption, but several other factors inﬂu-
ence this decision (anesthesiologist experience/comfort,
patient cooperation). Further, a recent report suggests
that ambulatory, outpatient PEVAR is safe in up to 40%
of patients.29 This is likely where this procedure is headed.
Last, this trial was conducted in centers of excellence
with experienced physicians, and thus the results need to
be considered in that context. Selected investigators were
well past their learning curve with both EVAR and the
preclose technique. A recent article30 reporting 82%
PEVAR technical success suggested that the learning curve
may be 30 cases. This conclusion, however, was drawn on
the basis of an unacceptable 45% single-operator early tech-
nical success rate with Prostar XL. On the basis of the
performance in our trial and the availability of procedure-
speciﬁc training with the ProGlide device, we would expect
the learning curve to be signiﬁcantly shorter.
With judicious patient selection and adequate operator
training and experience, excellent and sustainable out-
comes with PEVAR comparable to those achieved in this
trial will be realized. Approval of the Food and Drug
Administration for PEVAR with the Endologix endovascu-
lar system and the ProGlide vessel closure device studied in
this trial and the availability of an approved physician
training/certiﬁcation program have been accomplished.Implementation of the training program with speciﬁc
attention to hands-on bench training and live case demon-
stration followed by proctored case completion through
the learning curve to demonstrated proﬁciency is under-
way. As a result, this less-invasive alternative should be
offered to and will beneﬁt similarly selected patients.
CONCLUSIONS
Among trained operators and in suitably selected pa-
tients, a totally percutaneous approach to EVAR using the
Endologix sheath-based 21F endograft system with preclose
vessel closure facilitated by the ProGlide closure device is
safe with a low incidence of access-related complications.
PEVAR is less invasive, takes less time to complete and to
achieve hemostasis, and may positively inﬂuence other aspects
of the patient’s safety and overall experience. Keys to success
are intensive operator training and experience, careful patient
selection, and diligent attention to procedural conduct.
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Volume 59, Number 5 Marston 1193DISCUSSIONDr Zachary K. Baldwin (Jackson, Miss). Despite the lack of
high-quality evidence for efﬁcacy, percutaneous access for endovas-
cular aneurysm repair has become commonplace among vascular
interventionalists. In the right hands, it has the potential to miti-
gate the morbidity associated with open groin incision, speed re-
covery, and accelerate discharge. However, in the wrong hands
and without proper training and judgment, there is the potential
for grave complication.
With this in mind and with CMS looking over everyone’s
shoulder in terms of outcomes data and reimbursement, the au-
thors should be commended on putting together a thoughtful
multicenter trial of percutaneous EVAR and traditional EVAR.
The study provides level 1 evidence of noninferiority when
comparing percutaneous to open access. From a clinical stand-
point, PEVAR was found to either trend toward or signiﬁcantly
impact procedure time, time to hemostasis, blood loss, and mean
time to hospital discharge. The study outcomes suggest that
PEVAR has favorable impact on the perioperative course of
EVAR patents. Given the stent graft utilized, French size, and
closure device, these results appear to be applicable to other
EVAR devices on the market.
That being said, the core question of comparative effectiveness
research is which treatment works best, for whom, and under what
circumstances? Answering these questions using this study is some-
what difﬁcult given that the patient cohort is notable for being pre-
dominantly white males with large iliac vessels and average BMIs
<30. The morbidly obese are thought to be a group likely to
beneﬁt from a percutaneous approach. However, it is difﬁcult to
conﬁrm or deny these suspicions based on this particular study.
Iliac morphology may also play a role in deciding between percu-
taneous and open vessel access. It has been my experience that
advancing and withdrawing sheaths in borderline diameter arteries
with signiﬁcant calciﬁcation and/or tortuosity can increase shear at
the level of arteriotomy. Are such cases better approached percuta-
neously, or does open exposure mitigate potential injury?
Finally, one potential beneﬁt of percutaneous access is allow-
ing for an “awake” EVAR. Avoidance of a general anesthetic
should have an impact in terms of perioperative morbidity/mortal-
ity when performing EVAR. Unfortunately, there is little informa-
tion as to whether utilization of PEVAR impacted anesthetic
choice among participating physicians.
Dr Nelson and colleagues should be congratulated on a very
important and timely study that provides much needed evidence
for percutaneous access in performance of EVAR. I do not believe
that the study can be interpreted by interventionalists as a license
to access all patients percutaneously. Instead, the study provides
clear evidence of the percutaneous technique’s safety and will,
hopefully, set the stage for studies in the future deﬁning which pa-
tients beneﬁt most from a percutaneous approach.
Dr Peter R. Nelson. Thank you, Dr Baldwin, for your com-
ments and for your review of our manuscript. I assure you that you
are a candidate for PEVAR. I want to respond to one of the com-
ments that you made. I think we have to be a little careful extrap-
olating these data to all endovascular devices or all large-bore
access procedures since this study was conducted using a singleendovascular stent graft system. I fully realize that people are using
this technique for other systems, but this trial obviously was specif-
ically focused on one device.
With respect to your ﬁrst question on obesity, I think we all
feel that the obese patient is really where the PEVAR technique
could offer the most beneﬁt because the obese suffer the most
morbidity from groin wound complications. But, in designing a
rigorous clinical trial, we have to be cautious upfront because, in
the literature, the obese also have the highest complication rate
of percutaneous access. So in terms of this being the ﬁrst phase
of the trial, it was reasonable to exclusion. The 7-cm distance
required from the skin to the femoral artery was deﬁned by the
length of the micropuncture needle. We felt that if the needle
could not reach the femoral artery easily, then maybe that should
be an anatomic exclusion. We all know that you can indent the skin
and get access in those situations, but at least for the purposes of
the trial, 7 cm was the maximum length allowable.
Regarding your second question on anesthetic options used in
the trial, investigators came into the trial with a certain established
practice or preference in terms of what anesthetic strategy they
used, and we did not see a signiﬁcant change from this baseline
practice. I think that if you were a local anesthetic user before,
you used it in the trial. If you used general anesthetic, you used
it in the trial. We did not see people switching to local anesthesia,
and we did not require or suggest that in PEVAR cases. I think
your point is very important, however, because this technique deﬁ-
nitely opens the door to very feasible use of local anesthetic, which
could result in even shorter hospital stays and even move us toward
outpatient EVAR, and I think that is where we need to be
thinking.
Your third question on iliac morphology is an important ques-
tion. The trial focused most of the exclusion criteria on the com-
mon femoral artery anatomy and calciﬁcation, but we did collect
data on the degree of calciﬁcation in the iliac access vessels. The
amount of calciﬁcation as I showed was similar between groups
and it did not impact the success of the percutaneous access over-
all. Greater calciﬁcation did, however, result in an increased num-
ber of iliac interventions, such angioplasties and adjunctive stenting
for the access vessel. What I do in my practice is if I have someone
who has a heavily calciﬁed iliac access vessel, I still am comfortable
doing percutaneous, but in that case, I might more conservatively
use a series of hydrophilic dilators to sequentially dilate the access
to allow the device to pass. I personally have not had problems
with that affecting the success of percutaneous approach itself.
One additional comment regarding the inﬂuence of iliac anat-
omy is that tortuosity, which we did not critically scientiﬁcally eval-
uate in this trial, is a signiﬁcant variable. If you have a very tortuous
iliac system, and anyone who has done this will know, the Proglide
device is just a little bit short, such that, in a very tortuous iliac sys-
tem, you may have difﬁculty maintaining wire access. If the Pro-
glide device slides back into the iliac system, you have to traverse
that tortuosity twice at least to get the access and secure all of
your preclosure devices. Therefore, iliac tortuosity is something I
think worthy of looking at as you plan cases, since it poses some
challenges that may require some thought to ensure success.INVITED COMMENTARYWilliam A. Marston, MD, Chapel Hill, NCAs devices for endovascular aneurysm repair (EVAR) have
been packaged into smaller and more ﬂexible sheath systems, the
potential for percutaneous aneurysm repair has been realized
with the use of closure devices and speciﬁc pre-closure procedures.In this carefully designed and executed prospective random-
ized trial, the authors have compared standard surgical femoral ac-
cess EVAR (SEVAR) with percutaneous EVAR (PEVAR) using
two different devices designed for femoral artery closure. Sites
